Immune Cells in Infant Skin Are Wired to Overreact - and That May Explain Why Eczema Starts Young

Eczema affects nearly one in four children and frequently appears in the first months of life. It also has a habit of arriving first in a longer sequence of allergic conditions - asthma and food allergies often follow. That pattern has long suggested something specific about early childhood biology creates vulnerability, but the mechanism has been poorly understood. A study published in Nature offers a cellular explanation.

Researchers at the Icahn School of Medicine at Mount Sinai, Weill Cornell Medicine, and collaborating institutions used young mice to show that a specific immune cell type in early-life skin - the dendritic cell - is biologically primed to respond more intensely to allergens than its counterpart in adult skin. The finding was made in mice, a significant limitation for any immediate clinical translation, but the researchers believe it identifies a developmental window with direct relevance to human allergic disease.

Why the Timing Matters

"We found that allergy risk is shaped very early in life, when the skin's immune system is biologically programmed to overreact to allergens, with important consequences for understanding how immune-mediated diseases emerge and should be treated," said senior study author Shruti Naik, PhD, Associate Professor of Immunology and Immunotherapy and Dermatology at Mount Sinai. "By pinpointing the cells and hormonal signals that control this window of vulnerability, we open the door to strategies that could prevent allergic disease before it spreads from the skin to the lungs, gut, and beyond."

The concept of eczema as the opening stage of an "allergic march" - a progression from skin inflammation to respiratory and digestive allergies - is well established in clinical literature. What this study adds is a proposed biological basis for why that march so reliably begins in childhood rather than adulthood.

The Dendritic Cell Difference

Dendritic cells are sentinels. They patrol tissues, sample the environment for foreign material, and present what they find to other immune cells that then decide whether to mount an inflammatory response. The researchers found that dendritic cells in the skin of young mice respond more intensely to allergen exposure than those in adult mice - not because the young animals encounter more allergens, but because the cells themselves are differently calibrated.

The study identified hormonal signals that appear to govern this calibration, suggesting that the heightened reactivity of early-life skin immune cells is not a defect but a feature of normal developmental programming. The skin's immune system in early life may be tuned differently for reasons related to postnatal immune development - establishing tolerance to harmless environmental substances while building defenses against genuine threats. When that calibration goes wrong, the result is an inflammatory response to innocuous allergens.

The implications extend beyond eczema. If the early-life dendritic cell state can be modulated - by targeting the hormonal signals the researchers identified - it might be possible to reduce the probability of developing the initial sensitization that launches the allergic march. That would be a preventive strategy rather than a treatment for established disease.

Limits of the Mouse Model

The study was conducted in mice, and extrapolating mouse immunology findings to human clinical recommendations requires caution. Mouse and human skin differ in structure, cell composition, and developmental timing. The hormonal signals identified in the mouse model may not operate identically in humans, and the window of vulnerability may correspond to a different developmental period. Confirming these findings in human tissue - and eventually in clinical studies - would be necessary before any preventive approach could be designed.

The study was reported in the February 25, 2026, online issue of Nature (DOI: 10.1038/s41586-026-10162-x). The research team spanned multiple institutions, with Naik's lab at Mount Sinai leading the work alongside Weill Cornell Medicine collaborators.